| Literature DB >> 30813927 |
Ming Xue1, Jianfeng Xie1, Ling Liu1, Yingzi Huang1, Fengmei Guo1, Jingyuan Xu1, Yi Yang1, Haibo Qiu2.
Abstract
BACKGROUND: T helper (Th) cells regulate sepsis processes, including primary pathogen clear and secondary pathogen defence. The objectives of this study were to determine the early and dynamic alterations of Th1 and Th2 populations to community-acquired severe sepsis upon onset among previously immunocompetent patients and whether it was related to clinical outcomes.Entities:
Keywords: Community-acquired severe sepsis; ICU-acquired infection; Mortality; T helper cells
Year: 2019 PMID: 30813927 PMCID: PMC6391803 DOI: 10.1186/s12967-019-1811-9
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Fig. 1Values of Th1, Th2 and Th2/Th1 in heathy control, ICU control and septic groups upon enrollment. a Gating strategy used for flow cytometric analysis. CD3 positive (CD3+) cells were analysed and further specified according to size/granularity in E1. R1 in green represents CD3+ CD8− T cells, which approximately equal to CD4+ T cells while R2 in yellow stands for CD8+ T cells. Th1 cells are defined as INF-gamma+ cells in CD3–CD8+ cells as R3 shows in blue. Th2 cells are defined IL4+ cells in CD3–CD8+ cells as R4 shows in orange. Values of Th1 (b), Th2 (c) and Th2/Th1 (d) upon enrollment in heathy control, ICU control and septic groups are presented as scatter dot plots with lines for median value and quartiles
Characteristics of enrolled patients
| Characteristic | Healthy control | ICU control | Community-acquired severe sepsis | |||
|---|---|---|---|---|---|---|
| Overall | 28-Day survivors | 28-Day non-survivors | p | |||
| n = 71 | n = 53 (74.6%) | n = 18 (25.4%) | ||||
| Age (years) | 57.32 ± 23.27 | 69.00 ± 19.87 | 71.72 ± 15.54 | 71.85 ± 17.21 | 71.72 ± 10.23 | ns |
| < 60, n (%) | 2 | 2 | 15 | 12 | 3 | |
| 61–70, n (%) | 1 | 1 | 9 | 5 | 4 | |
| 71–80, n (%) | 2 | 2 | 23 | 15 | 8 | |
| 81–90, n (%) | 2 | 2 | 23 | 22 | 3 | |
| Gender (male/female) | 4/3 | 4/3 | 45/26 | 36/17 | 9/9 | ns |
| Admission sources (n, %) | ns | |||||
| Emergency | – | 1 (14.3) | 56 (78.9) | 40 (75.5) | 16 (88.9) | |
| Internal dept. | – | 2 (28.6) | 6 (8.5) | 6 (11.3) | 0 | |
| Surgical dept. | – | 4 (57.1) | 9 (12.7) | 7 (13.2) | 2 (11.1) | |
| Presumed infection site (n, %) | ns | |||||
| Lung | – | – | 50 (70.4) | 36 (67.92) | 14 (77.7) | |
| Abdomen | – | – | 11 (15.5) | 8 (15.09) | 3 (16.7) | |
| Cardiovascular system | – | – | 3 (4.2) | 3 (5.66) | 0 | |
| Bone or soft tissue | – | – | 1 (1.4) | 1 (1.89) | 0 | |
| Urinary tract | – | – | 6 (8.5) | 5 (9.43) | 1 (5.6) | |
| Aetiologya | ||||||
| Bacteria | – | – | 32 (45.1) | 21 (39.6) | 11 (61.1) | ns |
| Virus | – | – | 5 (7.0) | 3 (5.7) | 2 (11.1) | ns |
| Others or undetected | – | – | 34 (47.9) | 29 (54.7) | 5 (27.8) | ns |
| Comorbidities (n, %) | ||||||
| Hypertension | 0 | 3 (42.9) | 38 (53.5) | 28 (52.8) | 10 (55.6) | ns |
| Diabetes | 0 | 3 (42.9) | 20 (28.2) | 13 (24.5) | 7 (38.9) | ns |
| Chronic cardiac dysfunction | 0 | 2 (28.6) | 27 (38.0) | 20 (37.7) | 7 (38.9) | ns |
| Cerebrovascular disease | 0 | 0 | 28 (39.4) | 22 (41.5) | 6 (33.3) | ns |
| Chronic renal dysfunction 0 | 0 | 0 | 5(7.0) | 4(7.5) | 1(5.6) | ns |
| Smoker | ns | |||||
| Never | 6 (85.7) | 6 (85.7) | 47 (66.2) | 33 (62.3) | 14 (77.8) | |
| Previous (stopped > 3 months) | 0 (0) | 1 (14.3) | 14 (19.7) | 11 (20.8) | 3 (16.7) | |
| Former (stopped ≤ 3 months) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Current | 1 (14.3) | 0 (0) | 10 (14.1) | 9 (16.9) | 1 (5.6) | |
| Alcohol use | ns | |||||
| Never or daily intake ≤ 50 g of pure alcohol | 7 (100) | 6 (85.7) | 64 (90.1) | 46 (86.8) | 18 (100) | |
| Previous (daily intake > 50 g of pure alcohol, stopped > 3 months) | 0 (0) | 1 (14.3) | 3 (4.2) | 3 (5.7) | 0 (0) | |
| Former (daily intake > 50 g of pure alcohol, stopped ≤ 3 months) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Current intake (> 50 g of pure alcohol) | 0 (0) | 0 (0) | 4 (5.6) | 4 (7.5) | 0 (0) | |
| Severity scores | ||||||
| APACHE II | – | 19.51 ± 5.31 | 20.55 ± 5.95# | 19.51 ± 5.31 | 23.38 ± 6.19 | 0.04 |
| SOFA D0 | – | 6.00 ± 2.39 | 9.91 ± 3.11# | 9.70 ± 3.21 | 10.44 ± 2.93 | ns |
| D3 | – | – | 8.11 ± 3.66 | 7.43 ± 3.35 | 9.5 ± 4.01 | 0.04 |
| D7 | – | – | 7.02 ± 3.29 | 6.24 ± 3.01 | 9.13 ± 3.31 | 0.01 |
| Inflammatory and immune indicators | ||||||
| D0 (upon enrollment) | ||||||
| WBC (/μl) | 6.31 [5.23, 7.54] | 13.89 [8.57,16.22] | 13.66 [8.89, 20.14] | 13.66 [8.59, 18.92] | 14.61 [8.89, 22.23] | ns |
| ALC (/μl) | 2.74 [1.99, 2.86] | 1.07 [0.96, 2.22] | 0.59 [0.52, 0.90]# | 0.59 [0.51, 0.99] | 0.52 [0.51, 0.66] | ns |
| hs-CRP (mg/l) | – | 6 [0.81, 119] | 94.60 [44, 136]# | 96.50 [65.85, 146.50] | 85.20 [33.88, 126.30] | ns |
| PCT (μg/l) | – | 0.09 [0.05, 2.05] | 1.18 [0.34, 12.82]# | 0.98 [0.30,17.79] | 1.27 [0.47, 1.93] | ns |
| Treg (%) | 1.77 [1.11, 2.56] | 1.52 [1.07, 1.77] | 2.14 [1.44, 3.91] | 2.14 [1.49, 3.54] | 1.69 [0.39, 5.40] | ns |
| D3 | ||||||
| WBC (/μl) | – | – | 9.78 [7.35, 15.29] | 9.47 [7.17, 9.47] | 14.07 [7.68, 19.59] | 0.03 |
| ALC (/μl) | – | – | 0.93 [0.55, 1.30] | 0.99 [0.59, 1.42] | 0.76 [0.55, 0.83] | 0.02 |
| hs-CRP (mg/l) | – | – | 63.5 [36.6, 107] | 65.8 [41.5, 110] | 45 [24, 105.9] | ns |
| PCT (μg/l) | – | – | 0.87 [0.27, 2.53] | 0.90 [0.26, 3.53] | 0.53 [0.26, 2.15] | ns |
| Treg (%) | – | – | 1.94 [1.39, 2.86] | 1.97 [1.41, 2.87] | 1.47 [0.35, 2.55] | 0.05 |
| D7 | ||||||
| WBC (/μl) | – | – | 8.21 [6.08, 12.02] | 7.98 [5.90, 9.06] | 13.36 [6.30, 15.90] | 0.02 |
| ALC (/μl) | – | – | 0.97 [0.66, 1.28] | 0.99 [0.78, 1.29] | 0.62 [0.47, 1.11] | 0.02 |
| hs-CRP (mg/l) | – | – | 43.0 [14.75, 78.8] | 46.85 [15.98, 81.4] | 32.6 [13.45, 58.28] | ns |
| PCT (μg/l) | – | – | 0.28 [0.20, 0.58] | 0.21 [0.20, 0.46] | 0.69 [0.22, 1.37] | ns |
| Treg (%) | – | – | 1.38 [1.11, 2.17] | 1.37 [1.11, 1.89] | 2.17 [0.60, 3.91] | ns |
APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; WBC, white blood count; ALC, absolute lymphocyte count; hs-CRP, high-sensitivity C-reactive protein; PCT, procalcitonin; Treg (%), percentage of regulatory T cells in CD4 positive T cells
aReferred to any pathogen detected within 7 days upon enrolled; # Significant difference with p < 0.05 compared to ICU control. Chi square tests were used for categorical data, Student’s t-test for normally distributed continuous data and Mann–Whitney-U tests for nonnormally distributed data. Mean and standard deviations are shown for age and severity scores and medians and interquartile ranges are for all inflammatory and immune indicators
Fig. 2Values of Th1, Th2 and Th2/Th1 in community-acquired severe sepsis cohort stratified by 28-day survival status. Values of Th1 (a), Th2 (b) and Th2/Th1 (c) at different time points in community-acquired severe sepsis cohort stratified by 28-day survival status on D0, D3 and D7. The black scatter dot plots stand for 28-day survivors; the gray scatter dot plots stand for 28-day non-survivors; lines presented median value and quartiles. Values of Th1 (d), Th2 (e) and Th2/Th1 (f) on D0, D3 and D7 among 28-day survivors; Th1 (g), Th2 (h) and Th2/Th1 (i) on D0, D3 and D7 among 28-day non-survivors
Fig. 3Death hazard ratios in cox-proportional hazards models. a Hazard ratios for severity scores, absolute values of peripheral blood cell count and T helper population. Significant risk factors are in red; Factors without significance are in blue; Significant protective factors are in green. b Hazard ratios for severity scores, alterations of peripheral blood cell count and T helper population within study period. Significant risk factors are in red; Factors without significance are in blue; Significant protective factors are in green. APACHE is for acute physiology and chronic health evaluation; SOFA is for sequential organ failure assessment; WBC is for white blood count; ALC is for absolute lymphocyte count; ΔTh2/Th1 D7-3 is change of Th2/Th1 from D7 to D3; ΔTh2/Th1 D7-3 is change of Th2/Th1 from D7 to D3. Significant associations with p < 0.05 are in bold
Fig. 4Receiver operating characteristic (ROC) curves. The area under curves (AUCs) with 95% confidence interval (CI) were presented with ROC curves. APACHE is for acute physiology and chronic health evaluation; AUC is for area under curve; CI is for confidence interval; Th is for T helper
Fig. 5The persistent increasing of Th2/Th1 was associated with occurrence of ICU-acquired infections and 28-day death. a Depicts stratification by Th2/Th1 alterations. b Values of Th2/Th1 in subgroups. c Incidence of ICU-acquired infections of patients (n = 71) in subgroups. d Depicts survival curves of patients (n = 71) with community-acquired severe sepsis in subgroups
Characteristics of patients in subgroups stratified by alterations of Th2/Th1
| Characteristic | Early recovery | Late recovery | Non-recovery | p |
|---|---|---|---|---|
| Age, mean ± SD, years | 72.0 ± 16.8 | 75.7 ± 11.4 | 67.5 ± 16.2 | ns |
| Gender (male/female) | 25/10 | 10/9 | 10/7 | ns |
| Admission sources, n (%) | 0.03 | |||
| Emergency | 23 (65.7) | 18 (94.7) | 16 (94.1) | |
| Internal dept. | 5 (14.3) | 1 (5.3) | 0 | |
| Surgical dept. | 7 (20) | 0 | 2 (11.8) | |
| APACHE II, mean ± SD | 20.9 ± 5.3 | 19.5 ± 4.2 | 20.8 ± 8.0 | |
| SOFA, mean ± SD | ||||
| D0 | 9.3 ± 2.1 | 11.2 ± 3.1 | 9.6 ± 4.5 | ns |
| D3 | 6.3 ± 2.6 | 10.8 ± 3.3 | 8.2 ± 3.8 | < 0.001 |
| D7 | 6.0 ± 3.2 | 8.0 ± 2.5 | 7.9 ± 4.0 | ns |
| Presumed infection site, n (%) | ns | |||
| Lung | 22 (62.9) | 17 (89.5) | 11 (64.7) | |
| Abdomen | 6 (17.1) | 2 (10.5) | 3 (17.6) | |
| Cardiovascular system | 2 (5.7) | 0 | 1 (5.9) | |
| Bone or soft tissue | 0 | 0 | 1 (5.9) | |
| Urinary tract | 5 (14.3) | 0 | 1 (5.9) | |
| Comorbidities, n (%) | ||||
| Hypertension | 20 (57.1) | 11 (57.8) | 7 (41.2) | ns |
| Diabetes | 8 (22.9) | 6 (31.6) | 6 (35.3) | ns |
| Chronic cardiac dysfunction | 11 (31.4) | 12 (63.2) | 4 (23.5) | 0.03 |
| Cerebrovascular disease | 11 (31.4) | 9 (47.4) | 8 (47.1) | ns |
| Chronic renal dysfunction | 2 (5.7) | 2 (10.5) | 1 (5.9) | ns |
| Smoker | ns | |||
| Never | 23 (65.7) | 13 (68.4) | 11 (64.7) | |
| Previous (stopped > 3 months) | 8 (22.9) | 4 (21.1) | 2 (11.8) | |
| Former (stopped ≤ 3 months) | 0 (0) | 0 (0) | 0 (0) | |
| Current | 4 (11.4) | 2 (10.5) | 4 (23.5) | |
| Alcohol use | ns | |||
| Never or daily intake ≤ 50 g of pure alcohol | 31 (88.6) | 18 (94.7) | 15 (88.2) | |
| Previous (daily intake > 50 g of pure alcohol, stopped > 3 months) | 2 (5.7) | 1 (5.6) | 0 (0) | |
| Former (daily intake > 50 g of pure alcohol, stopped ≤ 3 months) | 0 (0) | 0 (0) | 0 (0) | |
| Current intake (> 50 g of pure alcohol) | 2 (5.7) | 0 (0) | 2 (11.8) | |
Chi square tests were used for categorical data, Student’s t-test for normally distributed continuous data and Mann–Whitney-U tests for nonnormally distributed data
APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment